On July 29th, Gese Bio announced a strategic collaboration with Porton Pharma Solutions (300363) subsidiary Porton Bio for their respective advantages in the field of gene therapy. Through the strong alliance, the two parties will jointly develop drug development services. Gese Bio has more complete core patent technology in the concept verification and process development of circRNA drugs, combined with Porton Bio's end-to-end gene and cell therapy service platform and resource advantages, to jointly promote technological innovation and clinical transformation, accelerate the landing of circRNA innovative therapy.